US and China Jiahe (02453): Guangzhou Taihe Cancer Hospital was approved to enter the “Hong Kong and Macau Pharmaceutical Connect” list of designated medical institutions

Zhitongcaijing · 1d ago

According to the Zhitong Finance App, the US and China Jiahe (02453) issued an announcement. Guangzhou Taihe Cancer Hospital, a subsidiary of the company, was approved by the Guangdong Provincial Health Commission and the Guangdong Drug Administration to enter the list of designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area on December 8, 2025.

The “Hong Kong-Macao Pharmaceutical Device Connect” is the core implementation initiative of the “Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical and Medical Device Supervision, Innovation and Development Work Plan”. Designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area can import and use the Guangdong-Hong Kong-Macao Greater Bay Area special pharmaceutical policy with approval, allowing designated medical institutions to use clinically urgently needed drugs and advanced medical devices already marketed in Hong Kong and Macao with approval.

This accreditation has made the company a professional oncology medical institution qualified to use innovative pharmaceutical devices in Hong Kong and Macau. The company can take the lead in introducing and using urgently needed drugs in the field of oncology that have already been listed in Hong Kong and Macau in China and have not yet been approved in China, including novel original research drugs, etc., to further broaden business boundaries, form a differentiated competitive advantage with the market, provide more cancer patients with urgently needed drugs, and strengthen the company's competitive advantage in the field of oncology medicine.

This move will also promote a deep connection between the company and Hong Kong and Macao pharmaceutical resources, and enhance the level of clinical diagnosis and treatment and scientific research capabilities. By introducing cutting-edge international pharmaceutical devices, optimizing cancer treatment plans, speeding up integration with international medical standards, helping to establish a high-level cancer disease diagnosis and treatment system, and continuously improving patient service experience and treatment effectiveness.